An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new international set of recommendations says that some children and teenagers with obesity can be treated with drugs known as GLP-1 receptor agonists. These are the same family of medicines that include semaglutide (the active drug in Ozempic and Wegovy). The guidance doesn’t say every child with obesity should get these drugs, but it opens the door for doctors to use them selectively, alongside other supports. GLP-1 receptor agonists are medicines that copy a natural chemical made in the gut called GLP-1. In plain terms, they help people feel less hungry and can slow how quickly the stomach empties after eating. That leads to eating less and losing weight for many adults. They were developed first to treat diabetes and then became widely used for weight management in adults. When people talk about “GLP-1s” they usually mean this class of drugs, not a single medicine. The new guidance is built on studies in adolescents and data carried over from adults showing that GLP-1s can produce meaningful weight loss and improve some health measures. But the research in kids is smaller and newer than the adult evidence. Trials in teenagers have shown modest-to-significant weight reductions for some patients, often when combined with diet and activity changes, but results vary. The guidance stresses selecting patients carefully — for example, those with severe obesity or obesity plus other health problems — rather than treating every young person who’s overweight. Why this matters: childhood obesity can lead to earlier and more serious health problems like diabetes, high blood pressure and heart disease. If a medicine helps a teen lose weight and improves those risk factors, it could change their health trajectory. For families and doctors struggling to manage severe obesity when behavior changes alone aren’t working, having an additional, evidence-based medical option is important. It could offer relief to kids who have persistent weight-related health issues despite other efforts. There are important caveats and risks. GLP-1s can have side effects such as nausea, stomach pain, vomiting and constipation. We don’t yet know the long-term effects of using these medicines during adolescence while bodies and brains are still developing. Some people shouldn’t use them — for example, those with certain medical histories — and doctors must weigh benefits versus risks for each child. Regulatory approval for pediatric use varies by country and by specific drug; guidance is not the same as universal approval. Bottom line: The new global guidance cautiously supports using GLP-1 drugs for some children and teens with obesity, but only in selected cases, with medical oversight, and alongside lifestyle and psychosocial support.
Source: CBC